Tau immunotherapies for Alzheimer’s disease

References

• Alzheimer’s A. 2016 Alzheimer’s disease facts and figures. Alzheimers Dement. 2016 Apr;12(4):459–509. PubMed PMID: 27570871.
   PubMedGoogle Scholar
• Todd S, Barr S, Roberts M, et al. Survival in dementia and predictors of mortality: a review. Int J Geriatr Psychiatry. 2013 Nov;28(11):1109–1124. PubMed PMID: 23526458.
   PubMed Web of Science ®Google Scholar
• Bloom GS. Amyloid-beta and tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014 Apr;71(4):505–508. PubMed PMID: 24493463.
   PubMed Web of Science ®Google Scholar
• Serrano-Pozo A, Frosch MP, Masliah E, et al. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006189. PubMed PMID: 22229116; PubMed Central PMCID: PMCPMC3234452.
   PubMed Web of Science ®Google Scholar
• Frisardi V, Solfrizzi V, Imbimbo PB, et al. Towards disease-modifying treatment of Alzheimer’s disease: drugs targeting beta-amyloid. Curr Alzheimer Res. 2010 Feb;7(1):40–55. PubMed PMID: 19939231.
   PubMed Web of Science ®Google Scholar
• Imbimbo BP, Ottonello S, Frisardi V, et al. Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease. Expert Rev Clin Immunol. 2012 Feb;8(2):135–149. PubMed PMID: 22288451.
   PubMed Web of Science ®Google Scholar
• Panza F, Solfrizzi V, Imbimbo BP, et al. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer’s disease: the point of no return? Expert Opin Biol Ther. 2014 Oct;14(10):1465–1476. PubMed PMID: 24981190.
   PubMed Web of Science ®Google Scholar
• Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008 Jul 19;372(9634):216–223. PubMed PMID: 18640458.
   PubMed Web of Science ®Google Scholar
• Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005 May 10;64(9):1553–1562. PubMed PMID: 15883316.
   PubMed Web of Science ®Google Scholar
• Fox NC, Black RS, Gilman S, et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005 May 10;64(9):1563–1572. PubMed PMID: 15883317.
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003 Jul 8;61(1):46–54. PubMed PMID: 12847155.
   PubMed Web of Science ®Google Scholar
• Geerts H, Spiros A, Roberts P. Impact of amyloid-beta changes on cognitive outcomes in Alzheimer’s disease: analysis of clinical trials using a quantitative systems pharmacology model. Alzheimers Res Ther. 2018 Feb 2;10(1):14. PubMed PMID: 29394903; PubMed Central PMCID: PMCPMC5797372.
   PubMedGoogle Scholar
• Tariot PN, Lopera F, Langbaum JB, et al. The Alzheimer’s prevention initiative autosomal-dominant Alzheimer’s disease trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer’s disease, including a placebo-treated noncarrier cohort. Alzheimers Dement (N Y). 2018;4:150–160. PubMed PMID: 29955659; PubMed Central PMCID: PMCPMC6021543.
   PubMedGoogle Scholar
• Strobel G. Alzheimer’s prevention initiative. J Alzheimers Dis. 2010;21(3):1025–1035. PubMed PMID: 20844340.
   PubMed Web of Science ®Google Scholar
• Jack CR Jr., Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010 Jan;9(1):119–128. PubMed PMID: 20083042; PubMed Central PMCID: PMCPMC2819840.
   PubMed Web of Science ®Google Scholar
• Jack CR Jr., Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013 Feb;12(2):207–216. PubMed PMID: 23332364; PubMed Central PMCID: PMCPMC3622225.
   PubMed Web of Science ®Google Scholar
• Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med. 2012 Aug 30;367(9):795–804. PubMed PMID: 22784036; PubMed Central PMCID: PMCPMC3474597.
   PubMed Web of Science ®Google Scholar
• Shin RW, Iwaki T, Kitamoto T, et al. Hydrated autoclave pretreatment enhances tau immunoreactivity in formalin-fixed normal and Alzheimer’s disease brain tissues. Lab Invest. 1991 May;64(5):693–702. PubMed PMID: 1903170.
   PubMed Web of Science ®Google Scholar
• Arendt T, Stieler JT, Holzer M. Tau and tauopathies. Brain Res Bull. 2016 Sep;126(Pt 3):238–292. PubMed PMID: 27615390.
   PubMed Web of Science ®Google Scholar
• Mandelkow EM, Mandelkow E. Biochemistry and cell biology of tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med. 2012 Jul;2(7):a006247. PubMed PMID: 22762014; PubMed Central PMCID: PMCPMC3385935.
   PubMed Web of Science ®Google Scholar
• Forner S, Baglietto-Vargas D, Martini AC, et al. Synaptic impairment in Alzheimer’s disease: a dysregulated symphony. Trends Neurosci. 2017;Jun;40(6):347–357. PubMed PMID: 28494972.
   PubMed Web of Science ®Google Scholar
• Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta Neuropathol. 2017 May;133(5):665–704. PubMed PMID: 28386764; PubMed Central PMCID: PMCPMC5390006.
   PubMed Web of Science ®Google Scholar
• Holtzman DM, Carrillo MC, Hendrix JA, et al. Tau: from research to clinical development. Alzheimers Dement. 2016 Oct;12(10):1033–1039. PubMed PMID: 27154059.
   PubMed Web of Science ®Google Scholar
• Goedert M, Spillantini MG, Jakes R, et al. Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron. 1989 Oct;3(4):519–526. PubMed PMID: 2484340.
   PubMed Web of Science ®Google Scholar
• Arai T, Ikeda K, Akiyama H, et al. Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick’s disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol. 2001 Feb;101(2):167–173. PubMed PMID: 11271372.
   PubMed Web of Science ®Google Scholar
• Schoch KM, DeVos SL, Miller RL, et al. Increased 4R-tau induces pathological changes in a human-tau mouse model. Neuron. 2016 Jun 1;90(5):941–947. PubMed PMID: 27210553; PubMed Central PMCID: PMCPMC5040069.
   PubMed Web of Science ®Google Scholar
• Love JE, Hayden EJ, Rohn TT. Alternative splicing in Alzheimer’s disease. J Parkinsons Dis Alzheimers Dis. 2015 Aug;2(2). DOI:10.13188/2376-922X.1000010. PubMed PMID: 26942228; PubMed Central PMCID: PMCPMC4772657.
   PubMedGoogle Scholar
• D’Souza I, Schellenberg GD. Regulation of tau isoform expression and dementia. Biochim Biophys Acta. 2005 Jan 3;1739(2–3):104–115. PubMed PMID: 15615630.
   PubMed Web of Science ®Google Scholar
• Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010 Jan 28;362(4):329–344. PubMed PMID: 20107219.
   PubMed Web of Science ®Google Scholar
• Kopeikina KJ, Hyman BT, Spires-Jones TL. Soluble forms of tau are toxic in Alzheimer’s disease. Transl Neurosci. 2012 Sep;3(3):223–233. PubMed PMID: 23029602; PubMed Central PMCID: PMCPMC3460520.
   PubMed Web of Science ®Google Scholar
• Shafiei SS, Guerrero-Munoz MJ, Castillo-Carranza DL. Tau oligomers: cytotoxicity, propagation, and mitochondrial damage. Front Aging Neurosci. 2017;9:83. PubMed PMID: 28420982; PubMed Central PMCID: PMCPMC5378766.
   PubMed Web of Science ®Google Scholar
• Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol. 2009 Mar;8(3):270–279. PubMed PMID: 19233037.
   PubMed Web of Science ®Google Scholar
• Kouri N, Whitwell JL, Josephs KA, et al. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol. 2011 May;7(5):263–272. PubMed PMID: 21487420.
   PubMed Web of Science ®Google Scholar
• Goedert M, Spillantini MG. Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer’s disease. Biochim Biophys Acta. 2000 Jul 26;1502(1):110–121. PubMed PMID: 10899436.
   PubMed Web of Science ®Google Scholar
• McKee AC, Cairns NJ, Dickson DW, et al. The first NINDS/NIBIB consensus meeting to define neuropathological criteria for the diagnosis of chronic traumatic encephalopathy. Acta Neuropathol. 2016 Jan;131(1):75–86. PubMed PMID: 26667418; PubMed Central PMCID: PMCPMC4698281.
   PubMed Web of Science ®Google Scholar
• Ayers JI, Giasson BI, Borchelt DR. Prion-like spreading in tauopathies. Biol Psychiatry. 2018 Feb 15;83(4):337–346. PubMed PMID: 28506438; PubMed Central PMCID: PMCPMC5640465.
   PubMed Web of Science ®Google Scholar
• Goedert M. The ordered assembly of tau is the gain-of-toxic function that causes human tauopathies. Alzheimers Dement. 2016 Oct;12(10):1040–1050. PubMed PMID: 27686274.
   PubMed Web of Science ®Google Scholar
• Goedert M, Masuda-Suzukake M, Falcon B. Like prions: the propagation of aggregated tau and alpha-synuclein in neurodegeneration. Brain. 2017 Feb;140(2):266–278. PubMed PMID: 27658420.
   PubMedGoogle Scholar
• Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009 Jul;11(7):909–913. PubMed PMID: 19503072; PubMed Central PMCID: PMCPMC2726961.
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K. Alzheimer’s pathogenesis: is there neuron-to-neuron propagation? Acta Neuropathol. 2011 May;121(5):589–595. PubMed PMID: 21516512.
   PubMed Web of Science ®Google Scholar
• Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol. 2011 Oct;70(4):532–540. PubMed PMID: 22028219; PubMed Central PMCID: PMCPMC3203752.
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K. Potential pathways of abnormal tau and alpha-synuclein dissemination in sporadic Alzheimer’s and Parkinson’s diseases. Cold Spring Harb Perspect Biol. 2016 Nov 1;8(11). PubMed PMID: 27580631; PubMed Central PMCID: PMCPMC5088528. DOI:10.1101/cshperspect.a023630
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K. Alzheimer’s disease: pathogenesis and prevention. Alzheimers Dement. 2012 May;8(3):227–233. PubMed PMID: 22465174.
   PubMed Web of Science ®Google Scholar
• Walker LC, Diamond MI, Duff KE, et al. Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol. 2013 Mar 1;70(3):304–310. PubMed PMID: 23599928; PubMed Central PMCID: PMCPMC3665718.
   PubMed Web of Science ®Google Scholar
• Braak H, Rub U, Gai WP, et al. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna). 2003 May;110(5):517–536. PubMed PMID: 12721813.
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K. Spreading of tau pathology in sporadic Alzheimer’s disease along cortico-cortical top-down connections. Cereb Cortex. 2018 Sep 1;28(9):3372–3384. PubMed PMID: 29982389; PubMed Central PMCID: PMCPMC6095209.
   PubMed Web of Science ®Google Scholar
• Medina M, Hernandez F, Avila J. New features about tau function and dysfunction. Biomolecules. 2016 Apr 19;6(2). PubMed PMID: 27104579; PubMed Central PMCID: PMCPMC4919916. DOI:10.3390/biom6020021
   PubMed Web of Science ®Google Scholar
• Huang Y, Wu Z, Zhou B. Behind the curtain of tauopathy: a show of multiple players orchestrating tau toxicity. Cell Mol Life Sci. 2016 Jan;73(1):1–21. PubMed PMID: 26403791.
   PubMed Web of Science ®Google Scholar
• Lemere CA. Immunotherapy for Alzheimer’s disease: hoops and hurdles. Mol Neurodegener. 2013 Oct 22;8:36. PubMed PMID: 24148220; PubMed Central PMCID: PMCPMC4015631.
   PubMed Web of Science ®Google Scholar
• Panza F, Solfrizzi V, Seripa D, et al. Tau-centric targets and drugs in clinical development for the treatment of Alzheimer’s disease. Biomed Res Int. 2016;2016:3245935. PubMed PMID: 27429978; PubMed Central PMCID: PMCPMC4939203.
   PubMed Web of Science ®Google Scholar
• Ruthirakuhan M, Herrmann N, Suridjan I, et al. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer’s disease. Expert Opin Pharmacother. 2016 Dec;17(18):2417–2429. PubMed PMID: 27825018.
   PubMed Web of Science ®Google Scholar
• Lee SH, Le Pichon CE, Adolfsson O, et al. Antibody-mediated targeting of tau in vivo does not require effector function and microglial engagement. Cell Rep. 2016 Aug 9;16(6):1690–1700. PubMed PMID: 27475227.
   PubMed Web of Science ®Google Scholar
• Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology. 2014 Jan;76(Pt A):27–50. PubMed PMID: 23891641.
   PubMed Web of Science ®Google Scholar
• Graham WV, Bonito-Oliva A, Sakmar TP. Update on Alzheimer’s disease therapy and prevention strategies. Annu Rev Med. 2017 Jan 14;68:413–430. PubMed PMID: 28099083.
   PubMed Web of Science ®Google Scholar
• Monsonego A, Nemirovsky A, Harpaz I. CD4 T cells in immunity and immunotherapy of Alzheimer’s disease. Immunology. 2013 Aug;139(4):438–446. PubMed PMID: 23534386; PubMed Central PMCID: PMCPMC3719061.
   PubMed Web of Science ®Google Scholar
• Rosenmann H, Grigoriadis N, Karussis D, et al. Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol. 2006 Oct;63(10):1459–1467. PubMed PMID: 17030663.
   PubMedGoogle Scholar
• Mably AJ, Kanmert D, Mc Donald JM, et al. Tau immunization: a cautionary tale? Neurobiol Aging. 2015 Mar;36(3):1316–1332. PubMed PMID: 25619661.
   PubMed Web of Science ®Google Scholar
• Wagshal D, Sankaranarayanan S, Guss V, et al. Divergent CSF tau alterations in two common tauopathies: alzheimer’s disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):244–250. PubMed PMID: 24899730; PubMed Central PMCID: PMCPMC4256124.
   PubMed Web of Science ®Google Scholar
• Sato C, Barthélemy NR, Mawuenyega KG, et al. Tau kinetics in neurons and the human central nervous system. Neuron. 2018 May 16;98(4):861–864.
   PubMed Web of Science ®Google Scholar
• Chen Z, Mengel D, Keshavan A, et al. Alzheimers dement. Alzheimer’s Dementia. 2019 Mar;15(3):487–496. Epub 2018 Nov 9.
   PubMedGoogle Scholar
• Yu YJ, Watts RJ. Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics. 2013 Jul;10(3):459–472. PubMed PMID: 23549647; PubMed Central PMCID: PMCPMC3701773.
   PubMed Web of Science ®Google Scholar
• Menendez-Gonzalez M, Perez-Pinera P, Martinez-Rivera M, et al. Immunotherapy for Alzheimer’s disease: rational basis in ongoing clinical trials. Curr Pharm Des. 2011;17(5):508–520. PubMed PMID: 21375481.
   PubMed Web of Science ®Google Scholar
• Sigurdsson EM. Tau immunotherapies for Alzheimer’s disease and related tauopathies: progress and potential pitfalls. J Alzheimers Dis. 2018;64(s1):S555–S565. PubMed PMID: 29865056; PubMed Central PMCID: PMCPMC6171771.
   PubMedGoogle Scholar
• Montagne A, Zhao Z, Zlokovic BV. Alzheimer’s disease: A matter of blood-brain barrier dysfunction? J Exp Med. 2017 Nov 6;214(11):3151–3169. PubMed PMID: 29061693; PubMed Central PMCID: PMCPMC5679168.
   PubMed Web of Science ®Google Scholar
• Kontsekova E, Zilka N, Kovacech B, et al. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model. Alzheimers Res Ther. 2014;6(4):44. PubMed PMID: 25478017; PubMed Central PMCID: PMCPMC4255368.
   PubMed Web of Science ®Google Scholar
• Novak P, Schmidt R, Kontsekova E, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol. 2017 Feb;16(2):123–134. PubMed PMID: 27955995.
   PubMed Web of Science ®Google Scholar
• Terwel D, Lasrado R, Snauwaert J, et al. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J Biol Chem. 2005 Feb 4;280(5):3963–3973. PubMed PMID: 15509565.
   PubMed Web of Science ®Google Scholar
• Theunis C, Crespo-Biel N, Gafner V, et al. Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One. 2013;8(8):e72301. PubMed PMID: 23977276; PubMed Central PMCID: PMCPMC3747157.
   PubMed Web of Science ®Google Scholar
• Hung SY, Fu WM. Drug candidates in clinical trials for Alzheimer’s disease. J Biomed Sci. 2017 Jul 19;24(1):47. PubMed PMID: 28720101; PubMed Central PMCID: PMCPMC5516350.
   PubMed Web of Science ®Google Scholar
• Panza F, Solfrizzi V, Seripa D, et al. Tau-based therapeutics for Alzheimer’s disease: active and passive immunotherapy. Immunotherapy. 2016 Sep;8(9):1119–1134. PubMed PMID: 27485083.
   PubMed Web of Science ®Google Scholar
• Bright J, Hussain S, Dang V, et al. Human secreted tau increases amyloid-beta production. Neurobiol Aging. 2015 Feb;36(2):693–709. PubMed PMID: 25442111.
   PubMed Web of Science ®Google Scholar
• Qureshi IA, Tirucherai G, Ahlijanian MK, et al. A randomized, single ascending dose study of intravenous BIIB092 in healthy participants. Alzheimers Dement (N Y). 2018;4:746–755. PubMed PMID: 30581980; PubMed Central PMCID: PMCPMC6298197.
   PubMedGoogle Scholar
• Kfoury N, Holmes BB, Jiang H, et al. Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem. 2012 Jun 1;287(23):19440–19451. PubMed PMID: 22461630; PubMed Central PMCID: PMCPMC3365982.
   PubMed Web of Science ®Google Scholar
• Holmes BB, Furman JL, Mahan TE, et al. Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):E4376–85. PubMed PMID: 25261551; PubMed Central PMCID: PMCPMC4205609.
   PubMed Web of Science ®Google Scholar
• Yanamandra K, Jiang H, Mahan TE, et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol. 2015 Mar;2(3):278–288. PubMed PMID: 25815354; PubMed Central PMCID: PMCPMC4369277.
   PubMed Web of Science ®Google Scholar
• Yanamandra K, Kfoury N, Jiang H, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013 Oct 16;80(2):402–414. PubMed PMID: 24075978; PubMed Central PMCID: PMCPMC3924573.
   PubMed Web of Science ®Google Scholar
• West T, Hu Y, Verghese PB, et al. Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer’s disease and other tauopathies. J Prev Alzheimers Dis. 2017;4(4):236–241. PubMed PMID: 29181488.
   PubMed Web of Science ®Google Scholar
• Buee L, Bussiere T, Buee-Scherrer V, et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000 Aug;33(1):95–130. PubMed PMID: 10967355.
   PubMed Web of Science ®Google Scholar
• Troquier L, Caillierez R, Burnouf S, et al. Targeting phospho-Ser422 by active tau immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res. 2012 May;9(4):397–405. PubMed PMID: 22272619; PubMed Central PMCID: PMCPMC3637173.
   PubMed Web of Science ®Google Scholar
• Czerkowicz J, Chen W, Wang Q, et al. Pan-tau antibody Biib076 exhibits promising safety and biomarker profile in cynomolgus monkey toxicity study. Alzheimer’s Dementia. 2017;13(7):P1271.
   Google Scholar
• Alam R, Driver D, Wu S, et al. Preclinical characterization of an antibody [LY3303560] targeting aggregated tau. Alzheimer’s Dementia. 2017;13(7):P592–P593.
   PubMedGoogle Scholar
• Vitale F, Giliberto L, Ruiz S, et al. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice. Acta Neuropathol Commun. 2018 Aug 22;6(1):82. PubMed PMID: 30134961; PubMed Central PMCID: PMCPMC6103963.
   PubMedGoogle Scholar
• Novak P, Kontsekova E, Zilka N, et al. Ten years of tau-targeted immunotherapy: the path walked and the roads ahead. Front Neurosci. 2018;12:798. PubMed PMID: 30450030; PubMed Central PMCID: PMCPMC6224648.
   PubMed Web of Science ®Google Scholar